GlaxoSmithKline plc (GSK) – Financial and Strategic SWOT Analysis Review

GlaxoSmithKline plc (GSK) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
106
Pharmaceuticals and Healthcare
United Kingdom

GlaxoSmithKline plc (GSK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline plc (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies. It focuses on the development, manufacture and commercialization of pharmaceutical and consumer health related products. The company offers medicines for the treatment of various diseases such as infections, asthma, diabetes, cardiovascular, mental health and digestive conditions. GSK’s research and development activities focus on the development of medicines and vaccines for HIV/AIDS, tuberculosis and malaria, among others. It operates research facilities in the France, Germany, the UK, Belgium, Spain, the US, Canada, and Singapore, China. GSK is headquartered in Middlesex, the UK.

GSK aims at offering high quality medicines and vaccines to enhance the quality of human life around the world. Its strategy is to improve long-term financial performance with a diversified business model, enhance R&D returns, and deliver a diverse line of products, while simplifying its operating model. The company also aims at maintaining its existing partnerships and entering into new collaborative agreements to augment its services.

GlaxoSmithKline plc Key Recent Developments

Mar 17, 2015: GSK Selects Veeva as Global Multichannel CRM Partner
Mar 17, 2015: GSK becomes partner in new global fund to accelerate dementia research
Mar 10, 2015: GSK announces major new commitment to Asia
Mar 06, 2015: GSK Reportedly Laying Off 110 Employees In China For Violating Policy
Feb 26, 2015: GlaxoSmithKline announces changes to its Board

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
GlaxoSmithKline plc – Key Facts 6
GlaxoSmithKline plc – Key Employees 7
GlaxoSmithKline plc – Key Employee Biographies 8
GlaxoSmithKline plc – Major Products and Services 10
GlaxoSmithKline plc – Pharmaceutical Pipeline Products Data 12
GlaxoSmithKline plc, Pipeline Products by Therapy Area 12
GlaxoSmithKline plc, Pipeline Products by Development Phase 13
GlaxoSmithKline plc – Medical Equipment Pipeline Products Data 29
GlaxoSmithKline plc Pipeline Products by Equipment Type 29
GlaxoSmithKline plc Pipeline Products by Development Stage 30
GlaxoSmithKline plc – History 31
GlaxoSmithKline plc – Company Statement 52
GlaxoSmithKline plc – Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
GlaxoSmithKline plc – Key Manufacturing Facilities 65
Joint Venture 65
Section 2 – Company Analysis 66
GlaxoSmithKline plc – Business Description 66
GlaxoSmithKline plc – Corporate Strategy 67
GlaxoSmithKline plc – SWOT Analysis 68
SWOT Analysis – Overview 68
GlaxoSmithKline plc – Strengths 68
Strength – Leading Product Categories 68
Strength – Focused Research and Development Capabilities 68
Strength – Leading Market Position 68
GlaxoSmithKline plc – Weaknesses 70
Weakness – False Advertisements and Law Violations 70
Weakness – Product Defects 70
Weakness – Unsuccessful Clinical Trials 70
GlaxoSmithKline plc – Opportunities 71
Opportunity – Changing Demographics 71
Opportunity – Late Stage Pipeline Products 71
Opportunity – Strategic Initiatives 71
GlaxoSmithKline plc – Threats 72
Threat – Uncertain R&D Outcomes 72
Threat – Government Regulations 72
Threat – Competitive Pressures 72
GlaxoSmithKline plc – Key Competitors 73
Section 3 – Company Financial Ratios 74
Financial Ratios – Capital Market Ratios 74
Financial Ratios – Annual Ratios 75
Performance Chart 77
Financial Performance 77
Financial Ratios – Interim Ratios 78
Financial Ratios – Ratio Charts 79
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances 80
GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 80
GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 81
GlaxoSmithKline plc, Medical Equipment, Deals By Year, 2009 to YTD 2015 82
GlaxoSmithKline plc, Medical Equipment, Deals By Type, 2009 to YTD 2015 83
GlaxoSmithKline plc, Recent Deals Summary 84
Section 5 – Company’s Recent Developments 85
Mar 17, 2015: GSK becomes partner in new global fund to accelerate dementia research 85
Mar 17, 2015: GSK Selects Veeva as Global Multichannel CRM Partner 87
Mar 10, 2015: GSK announces major new commitment to Asia 88
Mar 06, 2015: GSK Reportedly Laying Off 110 Employees In China For Violating Policy 89
Feb 26, 2015: GlaxoSmithKline announces changes to its Board 90
Feb 16, 2015: GlaxoSmithKline Promotes Jack Bailey As President For North America 91
Feb 05, 2015: NEOMED creates a new Biologics and Vaccine Centre of Excellence 92
Feb 05, 2015: GSK To Reduce 27 Positions At Hamilton Facility 93
Feb 04, 2015: Unaudited Preliminary Results Announcement for the year ended 31 December 2014 94
Jan 26, 2015: GSK extends its price-freeze commitment to ten years for countries graduating from Gavi support 101
Section 6 – Appendix 102
Methodology 102
Ratio Definitions 102
About GlobalData 106
Contact Us 106
Disclaimer 106



List of Tables
GlaxoSmithKline plc, Key Facts 6
GlaxoSmithKline plc, Key Employees 7
GlaxoSmithKline plc, Key Employee Biographies 8
GlaxoSmithKline plc, Major Products and Services 10
GlaxoSmithKline plc, Number of Pipeline Products by Therapy Area 12
GlaxoSmithKline plc, Number of Pipeline Products by Development Stage 13
GlaxoSmithKline plc, Pipeline Products By Therapy Area and Development Phase 14
GlaxoSmithKline plc Number of Pipeline Products by Equipment Type 29
GlaxoSmithKline plc Pipeline Products by Equipment Type 29
GlaxoSmithKline plc Number of Pipeline Products by Development Stage 30
GlaxoSmithKline plc Pipeline Products by Development Stage 30
GlaxoSmithKline plc, History 31
GlaxoSmithKline plc, Other Locations 54
GlaxoSmithKline plc, Subsidiaries 54
GlaxoSmithKline plc, Key Manufacturing Facilities 65
GlaxoSmithKline plc, Joint Venture 65
GlaxoSmithKline plc, Key Competitors 73
GlaxoSmithKline plc, Ratios based on current share price 74
GlaxoSmithKline plc, Annual Ratios 75
GlaxoSmithKline plc, Interim Ratios 78
GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 80
GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 81
GlaxoSmithKline plc, Medical Equipment, Deals By Year, 2009 to YTD 2015 82
GlaxoSmithKline plc, Medical Equipment, Deals By Type, 2009 to YTD 2015 83
GlaxoSmithKline plc, Recent Deals Summary 84
Currency Codes 102
Capital Market Ratios 102
Equity Ratios 103
Profitability Ratios 103
Cost Ratios 104
Liquidity Ratios 104
Leverage Ratios 105
Efficiency Ratios 105



List of Figures
GlaxoSmithKline plc, Pipeline Products by Therapy Area 12
GlaxoSmithKline plc, Pipeline Products by Development Phase 13
GlaxoSmithKline plc Pipeline Products by Equipment Type 29
GlaxoSmithKline plc Pipeline Products by Development Stage 30
GlaxoSmithKline plc, Performance Chart (2010 – 2014) 77
GlaxoSmithKline plc, Ratio Charts 79
GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 80
GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 81
GlaxoSmithKline plc, Medical Equipment, Deals By Year, 2009 to YTD 2015 82
GlaxoSmithKline plc, Medical Equipment, Deals by Type, 2009 to YTD 2015 83

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.